Showing results (21-30 of 51) with videos related to

Sort By:
Pageof 6
Blood|September 20, 2023
Integrated epigenetic and transcriptional single-cell analysis of t(11;14) multiple myeloma and its BCL2 dependencyNoémie Leblay, Sungwoo Ahn, Rémi Tilmont, et al.
Leukemia Research|August 6, 2011
Expression, adverse prognostic significance and therapeutic small molecule inhibition of Polo-like kinase 1 in multiple myelomaRobert P Evans, Greg Dueck, Roger Sidhu, et al.
Blood|January 14, 2021
Multiple cereblon genetic changes are associated with acquired resistance to lenalidomide or pomalidomide in multiple myelomaSarah Gooding, Naser Ansari-Pour, Fadi Towfic, et al.
British Journal of Haematology|October 11, 2014
Thalidomide-prednisone maintenance following autologous stem cell transplant for multiple myeloma: effect on thrombin generation and procoagulant markers in NCIC CTG MY.10Michael J Kovacs, Gwynivere A Davies, Judy-Anne W Chapman, et al.
Blood Advances|December 7, 2020
A large meta-analysis establishes the role of MRD negativity in long-term survival outcomes in patients with multiple myelomaNikhil C Munshi, Herve Avet-Loiseau, Kenneth C Anderson, et al.
BMC Bioinformatics|March 8, 2020
CNV Radar: an improved method for somatic copy number alteration characterization in oncologyDavid Soong, Jeran Stratford, Herve Avet-Loiseau, et al.
Annals of Hematology|February 18, 2021
Subcutaneous daratumumab in Asian patients with heavily pretreated multiple myeloma: subgroup analyses of the noninferiority, phase 3 COLUMBA studyShinsuke Iida, Takayuki Ishikawa, Chang Ki Min, et al.
Blood Cancer Journal|February 2, 2024
GPRC5D as a novel target for the treatment of multiple myeloma: a narrative reviewPaula Rodriguez-Otero, Niels W C J van de Donk, Kodandaram Pillarisetti, et al.
European Journal of Haematology|April 12, 2011
Alkaline phosphatase variation during carfilzomib treatment is associated with best response in multiple myeloma patientsMaurizio Zangari, Monette Aujay, Fenghuang Zhan, et al.
Cancer|April 17, 2024
Safety and efficacy of belantamab mafodotin with pembrolizumab in patients with relapsed or refractory multiple myelomaAttaya Suvannasankha, Nizar Bahlis, Suzanne Trudel, et al.
Pageof 6